AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00991445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exposure
Description: After a 15-20 cm midline skin incision is made, a medial parapatellar capsule incision is made. The incision is carried up through the insertion of the vastus medialis and into the rectus tendon. The patella is everted. The bone cuts are made and the prostheses are cemented in place. Local Infiltration Analgesia is used.
Study NCT03388307 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: unilateral laminotomy
Description: minimally invasive technique
Study NCT03388307 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: decompressive laminectomy
Description: classic surgery
Study NCT01449071 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusions at study weeks 0, 1, 2, and 3.
Study NCT01449071 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epratuzumab 400 mg
Description: Epratuzumab 400 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.
Study NCT01449071 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epratuzumab 1200 mg
Description: Epratuzumab 1200 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.
Study NCT01449071 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epratuzumab 100 mg
Description: Epratuzumab 100 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.
Study NCT01449071 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epratuzumab 600 mg
Description: Epratuzumab 600 mg infusions at study weeks 0, 1, 2, and 3.
Study NCT02024087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalantercept plus sorafenib
Description: Subcutaneous (SC) injection of dalantercept once every 3 weeks and oral sorafenib daily.
Study NCT00189709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: IV
Study NCT00189709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluconazole
Description: IV
Study NCT00929500 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAST program
Description: MAST program: twice a week for 4 months
Study NCT00613470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citalopram and escitalopram
Description: escitalopram tablets starting at 10 mg, increase to 20 mg at 4 weeks if QIDS-C16 > 5, keep at same dose if QIDS-C16 \< 5.~citalopram tablet or solution starting at 2o mg, increase to 40 mg at 4 weeks if QIDS-C16 > 5, keep at same dose if QIDS-C16 \< 5.
Study NCT03332693 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Leg weight raising
Study NCT03332693 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No exercise
Description: Volunteers will not participate in exercise
Study NCT03093324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 8700
Description: Administered as specified in the treatment arm.
Study NCT03093324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dimethyl Fumarate
Description: Administered as specified in the treatment arm.
Study NCT01700621 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix vaccine
Description: one 1.0 ml dose of oral rotavirus vaccine at 9 months of age
Study NCT01700621 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: measles-rubella vaccine
Description: one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine
Study NCT01700621 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: measles-rubella vaccine
Description: one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine
Study NCT04663360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adverse Drug Reaction (ADRe) Profile
Description: ADRe asks nurses to systematically check patients for the manifestation of itemised adverse side effects or undesirable effects of their primary care medicines, as listed in the BNF and manufacturers' Summaries of Product Characteristics (SmPCs), and seminal texts documenting known ADRs. Nurses are asked to share the identified problems with prescribers and pharmacists overseeing medicines charts.
Study NCT02592967 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-64041757 (Cohort 1A and 1B)
Description: JNJ-64041757 will be administered IV at a lower dose in Cohort 1A (1x10\^8 colony forming units \[CFU\] ) and at a higher dose in Cohort 1B (1x10\^9 CFU)
Study NCT02592967 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-64041757 (Cohort 2A and 2B)
Description: JNJ-64041757 will be administered intravenously (IV) once every 21 days at the recommended dose as determined in Cohort 1A or 1B.
Study NCT02925364 — intervention group
Intervention type: RADIATION
Intervention: magnetic resonance imaging (MRI)
Description: all participants will undergo a functional MRI and an anatomical MRI in a single session
Study NCT03282838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-15 (fasted)
Description: DFN-15 administered to fasted subjects
Study NCT03282838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-15 (fed)
Description: DFN-15 administered to fed subjects
Study NCT03282838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator Celebrex® (fed)
Description: Comparator (Celebrex®) administered to fed subjects
Study NCT03093506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose rhEpo
Description: 60IU/kg/week
Study NCT03093506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micro-dose rhEpo
Description: 20IU/kg/week
Study NCT03093506 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Saline
Study NCT04062890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigabatrin Pill
Description: Oral Vigabatrin Pill
Study NCT04062890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Oral Placebo Pill
Study NCT03902171 — intervention group
Intervention type: DEVICE
Intervention: Soberlink
Description: Soberlink delivers real-time blood alcohol results to people who support individuals in recovery from alcohol use disorder. In-Home Addiction Treatment program Care Team monitors and responds to results as part of care to improve treatment outcomes.
Study NCT02502110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: All recruited patients with paroxysmal atrial fibrillation will be randomly allocated to receive oral rosuvastatin 20mg/day or blank control from 7 days before ablation and last for 3 months.
Study NCT02412215 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacoemulsification with toric Nanoflex IOL implantation
Description: A self-sealing incision is made with a 2.2mm knife at 110°. Phacoemulsification is performed. The foldable nanoFlex toric IOL is injected in the capsular bag using the nanoPoint single-use injector system (STAAR) or 1620 sofTip Injector (ASICO). The IOL is rotated to align the cylinder axis with the steep corneal meridian using Z align function by Callisto Eye. Every movement of the IOL axis marks are noted.
Study NCT02412215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoFlex toric Intraocular Lens
Study NCT04089982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Chantix
Study NCT04089982 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo
Study NCT03611894 — intervention group
Intervention type: OTHER
Intervention: radiological comparison
Description: comparison between clinical and radiological characteristics
Study NCT02067793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRX-1074 1 mg
Description: Single intravenous administration of 1 mg into arm on Day 0
Study NCT02067793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intravenous injection into the arm on Day 0
Study NCT02067793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRX-1074 5 mg
Description: Single intravenous injection of 5 mg into the arm on Day 0
Study NCT02067793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRX-1074 10 mg
Description: Single intravenous injection of 10 mg into the arm on Day 0
Study NCT02994186 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: These are patients who will be having either Vertical Sleeve Gastrectomy or Roux-en-Y Gastric Bypass.
Study NCT02994186 — intervention group
Intervention type: OTHER
Intervention: Medical Weight Loss Program
Description: These are patients who will be starting a structured medical weight loss program.
Study NCT01768858 — intervention group
Intervention type: DRUG
Intervention: Adalimumab
Description: Adalimumab administered by subcutaneous injection, via pre-filled syringe or autoinjector pen
Study NCT00677196 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The stonebreaker arm (LMA Stonebreaker)
Description: The interventional device name is the LMA Stonebreaker pneumatic handheld lithotriptor.
Study NCT00677196 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic Lithotripsy (Swiss LithoClastR)
Description: Pneumatic lithotripsy, the Swiss LithoClastR during percutaneous nephrolithotripsy (PNL)
Study NCT02226458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-743
Study NCT03583606 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd3-EBO-Z
Description: Zaire ebolavirus vaccine administered by an IM injection into the deltoid as a single dose of 2 x 10\^11 virus particles (vp)).
Study NCT03583606 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Multi-Filo Ebola Vaccine
Description: A booster vaccination of replication defective MVA-BN-Filo administered by an IM injection into the deltoid as a single dose of 1 x 10\^8 Infectious Units (IU).
Study NCT03583606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5 mL normal saline administered via IM injection into the deltoid.
Study NCT02164838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Study NCT00532636 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation
Description: Mask ventilation in neutral and head extension position
Study NCT01762748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Description: Oral capsule with 200 mg lyophilized S. boulardii-17 (about 4x108 cells), 6 mg sucrose and 2.4 mg magnesium stearate (Floratil®).
Study NCT04366141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COVID-19 barrier box
Description: Attending anesthesiologists will use a plastic proprietary barrier enclosure for intubating patients in the intervention group to protect spreading aerosolized droplets from patient to health care provider.
Study NCT00866593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic Escitalopram
Description: 10mg/d or 20mg/d
Study NCT00866593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Innovator Escitalopram
Description: 10mg/d or 20mg/d
Study NCT01604850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) 400 mg tablet was administered orally once daily.
Study NCT01604850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets was administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
Study NCT01604850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match SOF
Description: Placebo to match SOF was administered orally once daily.
Study NCT01604850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match RBV
Description: Placebo to match RBV was administered orally twice daily.
Study NCT05696639 — intervention group
Intervention type: PROCEDURE
Intervention: Aneurysm embolization
Description: All patients underwent Aneurysm embolization surgery, the cerebral venous will be observed intraoperatively.
Study NCT02510547 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CrossBoss Catheter
Description: Upfront use of the CrossBoss catheter for CTO lesion crossing
Study NCT02510547 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Antegrade Wire Escalation Strategy
Description: Upfront guidewire escalation strategy for CTO lesion crossing
Study NCT03006965 — intervention group
Intervention type: DRUG
Intervention: octocog alfa
Description: Pharmacokinetic Characterization of the Hemophilia A Population in Spain using an standalone web-based software
Study NCT03006965 — intervention group
Intervention type: DRUG
Intervention: rurioctocog alfa pegol
Description: Pharmacokinetic Characterization of the Hemophilia A Population in Spain using an standalone web-based software
Study NCT04900584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Checklist
Description: Checklist of guideline-based treatment before discharge
Study NCT04900584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Heart failure education before discharge
Study NCT04900584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone monitoring
Description: Telephone monitoring after discharge
Study NCT02680626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Given via transversus abdominis plane block
Study NCT02680626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Given via transversus abdominis plane block
Study NCT02680626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Given via transversus abdominis plane block
Study NCT05809765 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 8-week breath training program
Description: The participants were asked to be seated comfortably and raise their heads by 30° with the guidance of the investigator. During the inspiration process, the participants' abdomens bulged. They then held their breaths for 5 seconds before exhaling from their mouths for twice the duration of inspiration. Breath training was performed five times each hour throughout the three-hour duration of each dialysis session. In sum, the experimental group performed Triflow breath training 15 times during each dialysis session. The experimental group and the control group were randomly assigned by a coin toss.
Study NCT03157388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined Vancomycin and Gentamycin and Meropenem
Description: The following combined antibiotic regime will be administered for eradication of gut bacteria.~7 days combined antibiotic treatment, per oral route, once daily: vancomycin 500 mg (Vancomycin Hospira), powder for concentrate and gentamycin 40 mg (Hexamycin®), solution and meropenem 500 mg (Meropenem Hospira), powder for concentrate; The three drugs are dissolved and combined in approximately 100 ml of apple juice.
Study NCT01110447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: VSL#3® is made up of 4 strains of Lactobacilli (L. paracasei, L. plantarum, L. acidophilus and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacteria (B. longum, B. infantis, B. breve) and 1 strain of Streptococcus thermophilus. Dose would be 1 sachet per day (Each sachet containing 900 Billion CFU). The duration of treatment would be for 24 weeks
Study NCT01110447 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sachets contain corn starch. Dose: 1 sachet per day Duration of treatment: 24 weeks
Study NCT04354532 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic Banded Sleeve Gastrectomy
Description: The investigators performed Laparoscopic Sleeve Gastrectomy adding a MiniMizer Ring (Bariatric Solutions), a radiopaque silicone ring with four closing positions. The ring has a blue colour and for this reason it can easily be found back in revision surgery. The pulling lid is left in place with all closing positions in order to be adjusted postoperatively without having to place a new ring. The ring is slightly elastic and the fixation loops provide an anchorpoint to fix the ring in place which prevents it from slipping
Study NCT03026270 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Paraffin
Description: The application of paraffin wax will be performed with the patient in the supine position at rest for at least 10 min, then with an appropriate brush (5 cm wide), will spend several layers with the brush into two distinct groups, seven or ten layers depending on the outcome of randomisation, in the region of interest of the upper limb, being scarred, surrounded by a plastic film film remaining in the area for 15 minutes, and then discarded
Study NCT02788448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIVASURE CLOSURE DEVICE
Description: Large hole closure device
Study NCT01740661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: The subjects will be exposed to a cold (\~ 12° C) water immersion tub at the umbilical level for 20 minutes.
Study NCT01740661 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The subjects will be exposed to a non-cold (\~ 26° C) water immersion tub at the umbilical level for 20 minutes.
Study NCT03806062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: domperidone
Description: 10 mg domperidone 3 times a day after meals
Study NCT03806062 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: He-Ne laser (Bravo TrezaSerie) device
Description: The laser scan beam was adjusted to the size of the treated breast for 10 minutes with wave length 632.8 nm and power output 25 mw after the end of treatment session
Study NCT03806062 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: faradic current
Description: faradic stimulation (Body shaping System, model B-333, made in China) , at the following acupuncture points on both sides: Spleen 6 (Sanyinjiao), Liver 3 (Taichong) and Small Intestine 1 (Shaoze)
Study NCT04833998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extremecare
Description: The product under investigation (Extremecare) will be supplied as 120g use individual tubes to be applicated in the hands and feet twice a day (once in the morning and once in the evening) beginning with the first cycle of capecitabine and continuing until the end of the fifth cycle of chemotherapy.
Study NCT04833998 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cream will be supplied as 120g use individual tubes to be applicated in the hand and feet twice a day (once in the morning and once in the evening) during the fifth cycle of capecitabine therapy.
Study NCT03618953 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad-E6E7
Description: Adenovirus vaccine expressing mutant HPV E6 and E7
Study NCT03618953 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG1-E6E7
Description: MG1 Maraba oncolytic virus expressing mutant HPV E6 and E7
Study NCT03618953 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: monoclonal antibody; checkpoint inhibitor
Study NCT01661270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Pharmaceutical form: Concentrate for Solution for infusion; Route of administration: Intravenous
Study NCT01661270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Concentrate for Solution for infusion; Route of administration: Intravenous
Study NCT02457013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: Hygh flow nasal canula HFNC
Study NCT02457013 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nCPAP
Description: nasal nCPAP
Study NCT04590378 — intervention group
Intervention type: OTHER
Intervention: intensive care unit admission ratio
Description: intensive care unit admission ratio
Study NCT04638153 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recifercept
Description: Recifercept
Study NCT00496444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Starting Dose 20 mg/m\^2 administered subcutaneously (under the skin), daily, for ten days (Days 1 -10) of every 4 Week Cycle.
Study NCT00496444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Starting Dose 10 mg/Kg once daily by mouth, every day of 4 Week Cycle.
Study NCT01659307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 75mg
Description: Subjects randomised to aspirin 75mg will receive 1 container containing aspirin 75mg and 1 container containing placebo for the morning and 2 containers containing placebo for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.
Study NCT01659307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose powder
Description: Subjects randomised to placebo will receive 4 containers of placebo, 2 containers containing placebo for the morning and 2 containers containing placebo for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.